Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Interest Expenses (2016 - 2023)

Moleculin Biotech's Interest Expenses history spans 8 years, with the latest figure at $32.3 million for Q4 2023.

  • Quarterly results put Interest Expenses at $32.3 million for Q4 2023, up 25.73% from a year ago — trailing twelve months through Dec 2023 was $32.3 million (up 25.73% YoY), and the annual figure for FY2023 was $32.3 million, up 25.73%.
  • Interest Expenses for Q4 2023 was $32.3 million at Moleculin Biotech, up from $25.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $32.3 million in Q4 2023 to a low of $9.4 million in Q4 2019.
  • The 5-year median for Interest Expenses is $18.8 million (2021), against an average of $20.0 million.
  • The sharpest move saw Interest Expenses skyrocketed 60.85% in 2019, then increased 25.73% in 2023.
  • Year by year, Interest Expenses stood at $9.4 million in 2019, then surged by 47.24% to $13.9 million in 2020, then soared by 35.74% to $18.8 million in 2021, then skyrocketed by 36.51% to $25.7 million in 2022, then increased by 25.73% to $32.3 million in 2023.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $32.3 million, $25.7 million, and $18.8 million for Q4 2023, Q4 2022, and Q4 2021 respectively.